Sugi Predict

Sugi Predict / Compounds / SCHEMBL14228414

SCHEMBL14228414

SCHEMBL14228414

Cc1ccc(C)c(OCc2ccccc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ NPC1 O15118 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ TSHR P16473 1/20 0.51
▸ MRGPRX4 Q96LA9 2/20 0.50
▸ ALDH1A1 P00352 2/20 0.49
▸ HPGD P15428 1/20 0.49
▸ RXRA P19793 1/20 0.49
▸ RXRB P28702 1/20 0.49
▸ RXRG P48443 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ STAT3 P40763 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ KEAP1 Q14145 1/20 0.48
▸ NFE2L2 Q16236 1/20 0.48
▸ PTGER1 P34995 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL686650 0.87 MAPT (0.58) MAPTMAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL2880445 0.85 MRGPRX4 (0.66) MAPTMAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL25081934 0.84 MAPT (0.64) MAPTMAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL19286354 0.84 ALOX5 (0.58) MAPTMAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL27834056 0.84 ALDH1A1 (0.48) MAPTTDP1SMN1; SMN2NPC1RAB9A
SCHEMBL2912541 0.84 MAPT (0.55) MAPTMAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL8592978 0.83 SMN1; SMN2 (0.54) MAPTTDP1L3MBTL1SMN1; SMN2NPC1
SCHEMBL3149374 0.82 ALDH1A1 (0.48) MAPTTDP1SMN1; SMN2NPC1RAB9A
SCHEMBL15426843 0.82 FFAR4 (0.65) MAPTMAPK1TDP1L3MBTL1SMN1; SMN2
SCHEMBL22894882 0.82 PTGDR2 (0.58) MAPTMAPK1TDP1L3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023214629-A1 PHENOL COMPOUND-LINKED PENTAGALLOYL GLUCOSE DERIVATIVE AND USE THEREOF 주식회사 젠트리바이오 2023-11-09 — — WO disclosed
WO-2022152215-A1 ORGANIC COMPOUND, MIXTURE AND USE THEREOF 浙江光昊光电科技有限公司 2022-07-21 — — WO disclosed
WO-2022121224-A1 ORGANOBORON-NITROGEN COMPOUND, MIXTURE, COMPOSITION AND ORGANIC ELECTRONIC DEVICE 广州华睿光电材料有限公司 2022-06-16 — — WO disclosed
CN-109385175-A Anticorrosive paint paint suit ＫＣＣ公司 2019-02-26 — — CN disclosed
US-9703223-B2 Toner, developer, and toner cartridge HODOGAYA CHEMICAL CO., LTD. (JP) 2017-07-11 — — US disclosed
EP-3181555-A1 BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE Gilead Sciences, Inc. (US) 2017-06-21 — — EP disclosed
US-20170088554-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2017-03-30 — — US disclosed
US-9464096-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2016-10-11 — — US disclosed
CN-102131761-B Process for producing alpha-hydroxy ester compound 住友化学株式会社 2016-09-28 — — CN disclosed
US-20160152582-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-06-02 — — US disclosed
US-20160024104-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-28 — — US disclosed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 — — US disclosed
US-9096586-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-08-04 — — US disclosed
US-9006229-B2 Benzothiazole compounds and their pharmaceutical use GILEAD SCIENCES, INC. (US) 2015-04-14 — — US disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 — — US disclosed
US-8778874-B2 Glycopeptide antibiotic monomer derivatives NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2014-07-15 — — US disclosed
US-20140045818-A1 BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE GILEAD SCIENCES, INC. (US) 2014-02-13 — — US disclosed
US-20130281434-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-10-24 — — US disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 — — US disclosed
US-20080097078-A1 Antibacterial activity against vancomycin-resistant bacteria SHIONOGI & CO., LTD. (JP) 2008-04-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170088554-A1 THERAPEUTIC COMPOUNDS FURIN, NFATC1, NPC1 MAPT 640/4885MAPK1 68/4885TDP1 3992/4885
US-20140045818-A1 BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE FURIN, NFATC1, RUNX1 MAPT 333/4885MAPK1 196/4885TDP1 3138/4885
US-20130281434-A1 THERAPEUTIC COMPOUNDS NFATC1, FURIN, CD4 MAPT 929/4885MAPK1 1066/4885TDP1 4331/4885
US-20160024104-A1 THERAPEUTIC COMPOUNDS NFATC1, FURIN, NPC1 MAPT 665/4885MAPK1 72/4885TDP1 3966/4885
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 MAPT 1627/4885MAPK1 3248/4885TDP1 3466/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 MAPT 1627/4885MAPK1 3248/4885TDP1 3466/4885
US-20160152582-A1 THERAPEUTIC COMPOUNDS NFATC1, FURIN, CD4 MAPT 929/4885MAPK1 1066/4885TDP1 4331/4885
US-20080097078-A1 Antibacterial activity against vancomycin-resistant bacteria CSGALNACT1, MON2, NR2C2 MAPT 4669/4885MAPK1 1183/4885TDP1 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.